ClonOrgan Biotechnology

ClonOrgan Biotechnology is a pioneering Chinese biotechnology company specializing in xenotransplantation and regenerative medicine. The company utilizes advanced gene-editing technologies, such as CRISPR/Cas9 and somatic cell nuclear transfer, to develop genetically modified pigs as a sustainable source of organs and tissues for human transplantation. Their research focuses on eliminating xenoantigens and incorporating human protective genes to overcome immunological rejection and prevent the transmission of porcine endogenous retroviruses. ClonOrgan has achieved significant milestones in preclinical and investigator-initiated trials, including pig-to-human skin grafts and organ transplants in brain-dead recipients. The company aims to address the critical global shortage of donor organs by providing clinical-grade porcine kidneys, hearts, and livers.